Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 17/20 | 0.82 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.82 |
| ▸ | SSTR5 | P35346 | 15/20 | 0.77 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.77 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654970 | 0.96 | SSTR2 (0.85) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL29414545 | 0.94 | SSTR2 (0.84) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL30604479 | 0.92 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL21099762 | 0.91 | SSTR2 (0.78) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18712687 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL31632623 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL30163296 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL6369050 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL4827 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL29405608 | 0.89 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240181094-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2024-06-06 | — | — | US | claimed |
| US-20230293736-A1 | [161Tb]-BASED RADIOPEPTIDES | PAUL SCHERRER INSTITUTE (CH) | 2023-09-21 | — | — | US | claimed |
| EP-4232097-A1 | [161Tb]-BASED RADIOPEPTIDES | Universität Basel (CH) | 2023-08-30 | — | — | EP | claimed |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-06-01 | — | — | US | claimed |
| WO-2023051941-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-04-06 | — | — | WO | claimed |
| EP-3965751-B1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM ISOTOPE TECH MUNICH SE (DE) | 2022-12-28 | — | — | EP | claimed |
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM ISOTOPE TECH MUNICH SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2025-05-29 | — | — | US | disclosed |
| EP-4514405-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-12208145-B2 | [161 tb]-based radiopeptides | UNIVERSITÄT BASEL (CH) | 2025-01-28 | — | — | US | disclosed |
| EP-4232097-A1 | [161Tb]-BASED RADIOPEPTIDES | Universität Basel (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-4218749-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-06-01 | — | — | US | disclosed |
| WO-2023051941-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-04-06 | — | — | WO | disclosed |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3965751-B1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM ISOTOPE TECH MUNICH SE (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-20220304964-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208145-B2 | [161 tb]-based radiopeptides | SSTR1, SSTR4, SSTR3 | SSTR2 5/4885SSTR4 2/4885SSTR5 4/4885 |
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | SSTR1, SSTR3, SSTR2 | SSTR2 3/4885SSTR4 5/4885SSTR5 4/4885 |
| US-20230293736-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | SSTR2 6/4885SSTR4 2/4885SSTR5 4/4885 |
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | SSTR2 15/4885SSTR4 42/4885SSTR5 14/4885 |
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | SLC40A1, SLC7A11, GYPA | SSTR2 1096/4885SSTR4 1238/4885SSTR5 416/4885 |
| US-20220304964-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | PAH, SLCO1B1, SLCO2B1 | SSTR2 1216/4885SSTR4 1042/4885SSTR5 695/4885 |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | SSTR2 6/4885SSTR4 2/4885SSTR5 4/4885 |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | SSTR3, SLC43A1, SSTR1 | SSTR2 6/4885SSTR4 7/4885SSTR5 9/4885 |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | CD74, HAVCR2, CD4 | SSTR2 3660/4885SSTR4 3222/4885SSTR5 2904/4885 |
| US-20240181094-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | SSTR2 6/4885SSTR4 2/4885SSTR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.